The purpose of this study is to compare the dose distribution, monitor units (MUs) and radiation delivery time between volumetric-modulated arc (VMAT) and fix-beam intensity modulated radiotherapy (FB-IMRT) in skull-base and non-skull-base head and neck cancer (HNC). CT datasets of 8 skull-base and 7 non-skull-base HNC were identified. IMRT and VMAT plans were generated. The prescription dose ranged 45-70 Gy (1.8-2.2 Gy/fraction).
Introduction
Radiation therapy for head and neck cancer (HNC) is challenging due to the complicate shape of the planning target volumes (PTV), multiple integrated targets with different dose prescriptions and the large number of adjacent critical organs, especially when the tumor is located near the skull-base. Intensity modulated radiotherapy (IMRT) can reduce the dose to the organs at risk (OARs) while maintaining coverage of the target volumes. Although fix-beam IMRT (FB-IMRT) has yielded respectable dosimetry and patient outcomes (1-6), there is still room for improvement. In certain complex skull-base cases, one may have to compromise Technology in Cancer Research & Treatment, Volume 12, Number 1, February 2013 the tumor coverage and dose homogeneity in order to avoid delivering high doses to adjacent critical structures. Another drawback of FB-IMRT is the long duration required for radiation (RT) delivery, which may increase intrafraction motion error and exacerbate patients' claustrophobia under the mask. Increased thick mucus secretion during the radiation course also makes it difficult for the patient to tolerate prolonged treatment immobilization in the flat position. Finally, the peripheral dose and neutron contamination from the large number of monitor units (MUs) may increase the risk of secondary malignancy in young patients (7) . RapidArc (RA) is a method of volumetric intensity-modulated arc therapy (VMAT) which permits radiation delivery in gantry arc rotation with continuous motion of the multileaf collimator (MLC), varying dose rates (DR) and gantry speed (8) . It has been compared to multi-field IMRT in several studies that included brain tumors, prostate, anal canal, and cervical cancer (9-10). In HNC, some studies have shown improvements in target coverage, treatment-time efficiency, MUs saving, and OARs sparing favoring . Although RA may be beneficial in HNC, it is not clear which subsite or location of HNC would benefit the most from this method since none of the previously published studies have addressed this question specifically. RA also requires additional resources for planning and physic time for dose verification on phantoms. The aim of this pilot study is therefore to identify a subset of HNC patients who would most benefit RA by comparing the dose distribution, MUs and radiation delivery time between RA and FB-IMRT technique. We divide the patients into two categories: those with skull-base and those with non-skull-base tumors due to their relationship to different critical structures. Although motion is less with the skull-base tumors, they are harder to cover due to their vicinity to neural and optic structures. This is the first study that addresses the appropriateness of using RA vs. FB-IMRT in HNC by tumor location.
Materials and Methods

Patient Selection
CT datasets of 15 HNC patients treated with RA were identified. Clinical information, target volume, dose prescription are shown in Table I . Eight of these are skull-base cases, the other seven are non-skull-base cases. Skull-base cases were those with the primary tumor located in the nasopharynx, paranasal sinuses or parapharyngeal/parotid space with invasion of the skull-base. The remaining tumors are considered non-skull-base. Prescribed dose to the PTV is dependent on the tumor histology, location, and prior therapy received. Most tumors received 66-70 Gy in 30-33 factions.
Planning Objectives
For each patient, a RA and a FB-IMRT plan were generated on the Eclipse 8.9 treatment planning system (Varian Medical System, Palo Alto, CA) with the same goals and objectives. For all PTVs, the plans aimed to achieve a minimum dose at least 95% of the prescribed dose and a maximum dose less than 120% (as specified by the HNC protocols from the Radiation Therapy Oncology Group [RTOG]). Planning objectives for OARs were defined as follows: Brainstem: D2 cc (maximum dose to 2 cc of the brainstem) , 50 Gy; spinal cord: D1cc , 45 Gy; optic apparatus: D0.03cc , 50 Gy; temporal lobe (Tem-lobe): D5cc , 60 Gy; lens: D max (maximum dose) , the temporal-mandibular joint (TMJ), mandible, oral cavity, larynx and so on, the planning strategy was to minimize their involvement but no specific constraint was set. Fulfilling of the dose criteria for the brainstem and spinal cord received the highest priority, followed by the PTVs, the optic structures and then other OARs.
Planning Techniques
6 MV photon beams from a linear accelerator (Varian Medical System) equipped with a MLC with 120 leaves (spatial resolution of 5 mm at the isocenter for the central 20 cm and of 10 mm in the outer 20 cm). Both plans were optimized selecting a maximum DR of 600 MU/min. Ring control structures were created (0.52 cm volumetric expansion beginning from the PTV) for both RA and FB-IMRT plans to increase dose conformity and control the dose gradient outside of the PTV. In addition, the normal tissue objective (NTO) tool in Eclipse was utilized to further reduce the dose outside the target. Plan optimization in both cases was completely disentangled from the dose calculation and performed with IMRT Dose Volume optimizer (DVO) and RapidArc's Progressive Resolution Optimizer (PRO) that implemented in Eclipse, version 8.9.05. Minor adjustments of the constraints were made whenever it was found necessary in order to achieve the best result. For the IMRT plans, maximum no. of iterations was set at 1000 with maximum time was set at 100 minutes. The goal of the optimization was considered reached and the process terminated when the value of the objective function approached a minimum and showed no further decreasing in value. For the RA plans, optimization were continued to allow the optimizer to finish all four phases of optimization and terminated by itself. Dose calculation was performed with the Anisotropic Analytical Algorithm (AAA, version 8.6.02) using a grid of 2.5 mm for both RA and FB-IMRT plans.
RA Plans
Two coplanar arc of full gantry rotation (179.9-180.1) with opposite rotation (clock-wise and counter clock-wise) were used for each plan and optimized simultaneously. No avoidance sector was used in these plans. The collimator was rotated to 458 to minimize the "tongue and groove" effect. To achieve the desired level of modulation, the instantaneous dose rate (DR), MLC leaf positions and the gantry rotational speed were continuously varied by the RapidArc optimizer.
FB-IMRT Plans
Reference plans were computed as intensity modulation with fixed gantry and step and shoot technique. Plans were individually optimized using 7-9 coplanar fields selecting for each patient based on the best geometry. The IMRT beam angles were selected and optimized based on the PTV location, shape, extension and relationship to relevant OARs. The number of beam angels was: 7 in seven (7/8) and 9 in one (1/8) of eight skull-base cases; whereas it was 7 in five (5/7) and 9 in two (2/7) of seven non-skull-base cases. The collimator of all patients was rotated to a 45-degree angle. MLC leaf sequences were generated using step and shoot technique. Optimization objectives were identical as for RA plans.
Evaluation of Plans and Statistics
All plans were normalized to ensure that 95% of the PTV is covered by the 100% isodose line (IDL). Quantitative evaluation of the plans was performed using the standard dose-volume histogram (DVH). For the PTV, the parameters included mean dose, V93% and V115%, where Vn% 5 percentage of the PTV covered by n% of prescribed dose. The conformity of the plans was measured with a conformity index, defined as the ratio between the patient volume receiving 95% of the prescribed dose and the PTV target volume (as per RTOG protocol). Heterogeneity was described by the homogeneity index (HI 5 D5-D95). For the OARs, the analysis included the mean dose, maximum dose, a set of appropriate Vx (the volume of the target that receives a specified dose) and Dy (the maximum dose to a specified target volume) values. The average cumulative DVH for the PTV, OARs, and healthy tissue was built from the individual DVHs. These histograms were obtained by averaging the corresponding volumes for the whole patient cohort for each dose bin of 0.05 Gy.
The delivery parameters were recorded in terms of MUs per fraction and the radiation delivery time in terms of minutes. The delivery time was measured on the linear accelerator when the VMAT plans were delivered to the patients and verified by repeated on a phantom by a physicist. The FB-IMRT delivery time was generated by delivering the plan on a phantom by a physicist experienced with handling the machine. The delivery time included the beam-on time and the time for rotating gantry/collimator in between the fields (arcs) for both approaches.
Comparison of DVH MUs, and delivery times were performed separately for skull-base and non-skull-base cases using paired two-tailed Student's T-test. Wilcoxon Matched-pair Signed-rank Test using exact method was alternatively used when the data did not follow a normal distribution. Results were considered statistically significant for p-value , 0.05. 
Results
The dose distributions for FB-IMRT and RA plans in one skull-base and one non-skull-base case are shown in Figure 1 and Figure 2 . Table II shows the numerical findings from the DVH analysis of the PTV and OARs, MUs and treatment delivery time in skull-base cases. The findings for non-skullbase cases are summarized in Table III . Data are presented as averages over the investigated patients and errors indicated inter-patient variability at one standard deviation level.
In one skull-base case with a large and extensive nasal cavity/ paranasal sinus cancer where the PTV nearly abutted the optic apparatus, the FB-IMRT plan was unable to meet the dose constraints to the optic nerve and the optic chiasm without compromising the PTV coverage. For this case, the dose to the 0.03 cc of the ipsilateral optic nerve, contralateral optic nerve and optic chiasm was 56.7 Gy, 57.4 Gy and 61.9 Gy, respectively for FB-IMRT, and it was 43.0 Gy, 42.5 Gy, and 39.5 Gy, respectively for RA. All RA plans met the dose constraints to optic structures. When all skull-base cases were grouped together, both plans yield similar target volume coverage, homogeneity, and conformity. Overall, the V115% of PTV1 was larger for FB-IMRT (4.5 6 10.3% vs. 2.0 6 5.5%, p 5 0.031). Likewise, RA plans generated significant lower maximum chiasm dose (D03cc: 32 6 11 vs. 41 6 15 Gy, p 5 0.026), ipsilateral TMJ dose (D33: 42 6 14 vs. 46 6 9 Gy, p 5 0.016) and ipsilateral middle ear dose (mean dose: 43 6 9 vs. 38 6 10 Gy, p 5 0.020) than FB-IMRT plans. The maximum dose to the optic nerve, temporal lobe and oral cavity and the mean dose to the parotid, contralateral TMJ and oral cavity were higher for FB-IMRT, but the difference was not statistically significant (p-values all greater than 0.05). The dose to the brainstem was higher for RA than FB-IMRT (32.8 6 9.4 vs. 35.4 6 10.3, p 5 0.109), but the difference did not reach statistical significance. A subset analysis of the 6 patients with nasopharyngeal and paranasal sinus carcinoma (i.e. removing the two patients with parotid and auditory canal tumor) was performed and similar results were found except for V115% of PTV1 and ipsilateral TMJ dose (the difference did not reach statistical significance. The p values were 0.125 and 0.084).
In non-skull-base cases, target volume coverage, dose homogeneity and conformity and doses to normal tissues were similar between the two plans.
The delivery efficiency was reported in Table IV . There was a substantial reduction of 70% in MUs (486 6 95 vs. 1614 6 493, p , 0.001) and 73% in radiation deliver times (3.0 6 0.6 vs. 11.0 6 3.3 min, p , 0.001) favoring RA in all cases.
Discussion
This study reports a comparison between RA (using double coplanar arcs) and FB-IMRT in HNC patients with an emphasis on identifying the subsite of HNC that may benefit from RA dosimetrically. As stated, we found that both approaches yield similar target volume coverage and met the planning goals. However, the dosimetric benefit for RA was more apparent in skull-base cases, where there was a significantly and clinically relevant smaller hot spot (V115%) inside the PTV1, lower doses to the optic chiasm, the ipsilateral TMJ and the middle ear. In addition, there was a trend for lower dose to several other normal structures including the ipsilateral optic nerve, temporal lobe, parotid gland, the contralateral TMJ and the oral cavity. This came with at the expense of slightly higher brain stem doses. These data suggested that RA may be beneficial when the tumors are located close to the optic apparatus and temporal lobe, where it may be difficult to provide adequate coverage of the target volume without exceeding dose tolerance to these structures.
In non-skull-base cases, we did not find any dosimetric advantage to RA. These data are consistent with those reported by Wiezorek et al. (15) who reported a higher median parotid dose for RA compared to step and shoot IMRT in ten non-skull-base cases. This is in contrast to those reported by Vanetti et al. (11) , who found that two-arc RA plans can improved target coverage and OAR sparing in non-skull-base tumors (oropharynx, larynx and hypopharynx) compared to traditional IMRT. The difference in the results between these 2 reported series are unclear and may be related to the tumor size and shape, the patient anatomy and the experience of the planners with both planning systems. However, to date, no study has teased out which HNC patient would most benefit from RA dosimetrically and our data suggest that the main dosimetric benefit is for those with skull-base tumors.
Verbakel's research on both skull-base (nasopharynx) and non-skull-base (oropharynx and hypopharynx) HNC showed There was a trend of improved dose conformity for IMRT plans but the contralateral parotid sparing was improved with VMAT (13). Although it is difficult to compare treatment planning studies due to differences in prescribed doses, patient population, delineation of target volumes and dose measuring techniques, all published studies support that multiple arc VMAT can yield a similar or better tumor coverage and OARs sparing compared to IMRT, while using less MUs. Several studies have compared the delivery time and MU between VMAT or RA and FB-IMRT (11-16). Similar to ours, they all confirmed an advantage for RA over FB-IMRT, which is the efficient use of MUs. In general, RA used less than one third of the MUs required for FB-IMRT plans. This results in lower scatter doses from collimator transmission. Such scattered undesirable doses can increase the risk for developing a radiation-related secondary malignancy. Hall's study showed that IMRT was likely to double the incidence of second malignancies from about 1% to 1.75% when compared to conventional radiotherapy in patients surviving 10 years or more (7). Since younger patients have a long life expectancy and a higher risk of radiation-related secondary malignancy (17), RA is theoretically more beneficial to these patients in minimizing such risk.
Consistent with the literature (11, 16, 18) , we found that another major advantage for RA was the faster radiation delivery time. The amount of time required to deliver an RA plan was one third of that needed for a FB-IMRT plan. Faster delivery time means shorter time on the treatment table, which translates to less intrafraction motion, less claustrophobia, and more patient comfort. In pediatric patients, this may mean better cooperation and a lower requirement for sedation or general anesthesia. Overall, the shorter delivery time will enable improved clinical throughput and treating more patients per machine.
In summary, we found that RA was dosimetric better than FB-IMRT only in evaluated skull-base cases. It was not superior to FB IMRT in non-skull-base cases with the exception of fewer MUs and shorter radiation delivery time. Based on these data, we recommend the use of RA in patients with tumors located near the optic apparatus where tumor coverage may be compromised by optic dose constraint, claustrophobic patients who cannot tolerate prolong mask immobilization and pediatric patients with curable HNC who are at risk of developing a radiation-induced secondary malignancy.
